These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29112287)

  • 1. Synthesis, Biological Evaluation, and Molecular Modeling Study of Substituted Benzyl Benzamides as CETP Inhibitors.
    Abu Khalaf R; Sabbah D; Al-Shalabi E; Bishtawi S; Albadawi G; Abu Sheikha G
    Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29112287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Docking and Pharmacophore Modeling Studies of Fluorinated Benzamides as Potential CETP Inhibitors.
    Khalaf RA; Al-Rawashdeh S; Sabbah D; Abu Sheikha G
    Med Chem; 2017; 13(3):239-253. PubMed ID: 27823564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesteryl ester transfer protein (CETP) inhibitors.
    Hunt JA; Lu Z
    Curr Top Med Chem; 2009; 9(5):419-27. PubMed ID: 19519458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of Inhibition of Cholesteryl Ester Transfer Protein by Small Molecule Inhibitors.
    Chirasani VR; Sankar R; Senapati S
    J Phys Chem B; 2016 Aug; 120(33):8254-63. PubMed ID: 27111423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Molecular Modeling of Novel 3,5-Bis(trifluoromethyl) benzylamino Benzamides as Potential CETP Inhibitors.
    Khalaf RA; Awad M; Al-Qirim T; Sabbah D
    Med Chem; 2022; 18(4):417-426. PubMed ID: 34463228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
    Qiao JX; Wang TC; Adam LP; Chen AY; Taylor DS; Yang RZ; Zhuang S; Sleph PG; Li JP; Li D; Yin X; Chang M; Chen XQ; Shen H; Li J; Smith D; Wu DR; Leith L; Harikrishnan LS; Kamau MG; Miller MM; Bilder D; Rampulla R; Li YX; Xu C; Lawrence RM; Poss MA; Levesque P; Gordon DA; Huang CS; Finlay HJ; Wexler RR; Salvati ME
    J Med Chem; 2015 Nov; 58(22):9010-26. PubMed ID: 26524347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic potential of CETP inhibitors: a patent review.
    Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D
    Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
    Nicholls SJ; Nelson AJ
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):229-235. PubMed ID: 30610681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester transfer protein (CETP) inhibitors based on cyclic urea, bicyclic urea and bicyclic sulfamide cores.
    Liu J; Shao PP; Guiadeen D; Krikorian A; Sun W; Deng Q; Cumiskey AM; Duffy RA; Murphy BA; Mitra K; Johns DG; Duffy JL; Vachal P
    Bioorg Med Chem Lett; 2021 Jan; 32():127668. PubMed ID: 33161125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
    Sirtori CR
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback.
    Yang Z; Cao Y; Hao D; Yuan X; Zhang L; Zhang S
    J Biomol Struct Dyn; 2018 Aug; 36(10):2567-2580. PubMed ID: 28777919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacetrapib as a potential cardioprotective strategy.
    Di Bartolo BA; Nicholls SJ
    Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies of three cholesteryl ester transfer proteins and their interactions with known inhibitors.
    Wang Z; Niimi M; Ding Q; Liu Z; Wang L; Zhang J; Xu J; Fan J
    PLoS One; 2017; 12(8):e0180772. PubMed ID: 28767652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.